NCT07532525 2026-04-16
Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma
University of Michigan Rogel Cancer Center
Phase 1 Not yet recruiting
Clinical Trials
54 trialsNCT04108195 2026-04-13
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT04667663 2026-04-13
CPD-DARA
Cancer Trials Ireland
Phase 1 Active not recruiting
NCT04722146 2026-04-13
MajesTEC-2
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT05050097 2026-04-13
MonumenTAL-2
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT06768489 2026-04-13
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT03984097 2026-04-09
A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)
Takeda
Phase 1 Completed
NCT04902443 2026-04-08
Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT02659930 2026-04-01
Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma
National Institutes of Health Clinical Center (CC)
Phase 1 Active not recruiting
NCT04910568 2026-03-19
CAMMA 1
Genentech, Inc.
Phase 1 Active not recruiting
NCT05556798 2026-02-24
A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT05389423 2026-02-19
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT05651932 2026-02-10
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
K36 Therapeutics, Inc.
Phase 1 Recruiting
NCT05556616 2026-01-29
iinnovate-2
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1 Terminated
NCT05137054 2026-01-22
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Regeneron Pharmaceuticals
Phase 1 Recruiting
NCT01562405 2026-01-14
Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Massachusetts General Hospital
Phase 1 Active not recruiting
NCT05259839 2025-12-19
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
AbbVie
Phase 1 Active not recruiting
NCT03287908 2025-10-08
A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Amgen
Phase 1 Terminated
NCT04045795 2025-09-12
Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
Sanofi
Phase 1 Completed
NCT01198067 2025-09-04
Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT03828292 2025-08-19
An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments
GlaxoSmithKline
Phase 1 Completed
NCT01998971 2025-04-25
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Completed
NCT05828459 2025-03-20
First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors
Onward Therapeutics
Phase 1 Recruiting
NCT03269136 2025-03-18
PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma
Pfizer
Phase 1 Completed
NCT03582033 2024-12-24
A Safety Study of SEA-BCMA in Patients With Multiple Myeloma
Seagen Inc.
Phase 1 Terminated
NCT02939183 2024-09-26
INTREPID-1
Amgen
Phase 1 Completed
NCT02616640 2024-09-19
A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Celgene
Phase 1 Completed
NCT02400242 2024-07-09
Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma
Celgene
Phase 1 Terminated
NCT03143985 2024-05-24
Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma
Case Comprehensive Cancer Center
Phase 1 Completed
NCT01728259 2023-05-09
First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD
Barbara Ann Karmanos Cancer Institute
Phase 1 Terminated
NCT04895410 2023-03-06
Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma
AbbVie
Phase 1 Terminated
NCT01575925 2022-11-04
POM Renal
Celgene
Phase 1 Completed
NCT02415153 2022-04-25
Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT02283775 2021-07-09
PomdeSAR
Sanofi
Phase 1 Completed
NCT02569320 2021-06-15
HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT01999335 2021-04-27
A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma
Amgen
Phase 1 Terminated
NCT02431208 2021-04-02
A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
Hoffmann-La Roche
Phase 1 Completed
NCT02029950 2020-10-14
Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
National Cancer Institute (NCI)
Phase 1 Completed
NCT04355039 2020-08-19
INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma
Medical College of Wisconsin
Phase 1 Withdrawn
NCT01497093 2020-04-07
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Celgene
Phase 1 Completed
NCT03015922 2020-01-22
MUKeleven
University of Leeds
Phase 1 Unknown
NCT02189343 2019-11-21
Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma
Celgene
Phase 1 Completed
NCT01568294 2019-11-12
Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
Celgene
Phase 1 Completed
NCT03657420 2019-08-14
Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma
Massachusetts General Hospital
Phase 1 Withdrawn
NCT01722305 2019-07-22
Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma
Mayo Clinic
Phase 1 Completed
NCT02462525 2018-09-13
Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma
AbbVie
Phase 1 Terminated
NCT02071888 2018-07-18
Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors
Calithera Biosciences, Inc
Phase 1 Completed
NCT03023527 2018-05-23
Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma
PETHEMA Foundation
Phase 1 Terminated
NCT03424928 2018-02-07
A Pilot Bioequivalence Study of Pomalidomide
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1 Completed
NCT02103335 2017-11-22
Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma
Celgene
Phase 1 Completed